The pioglitazone safety warning issued in South Korea, which recommended prescribing with careful attention among those with high risk of bladder cancer, led to a moderate decrease in pioglitazone users.
Sung-Il Cho, MD, ScD
Advertisement
Articles by Sung-Il Cho, MD, ScD
Advertisement
Latest Updated Articles
- Prescribing Trend of Pioglitazone After Safety Warning Release in Korea
November 19th 2019
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps
5